Compare Nokia Corp (NOK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs BIO-TECHNE Corp — how do they compare? Nokia Corp trades at $10.79 (market cap $59.77B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Nokia Corp is far larger — about 5.3× BIO-TECHNE Corp's market cap, and Nokia Corp pays the higher dividend (1.53%). Which is the better fit depends on your goals.
| NOK | TECH | |
|---|---|---|
Market Cap | $59.77B | $11.34B |
Sector | Technology | Health |
52-Week High | $16.83 | $72.48 |
52-Week Low | $4.51 | $43.31 |
Enterprise Value | $57.71B | $11.36B |
Dividend Yield | 1.53% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue trends stabilize around $20B annually. The company maintains a solid balance sheet with $8.91B cash and reduced debt-to-asset ratio of 9.09 in 2025. Positive news includes AI-driven network expansion and Euro Stoxx 50 reinstatement, though cash flow volatility and competitive pressures persist.
Outlook: Growth is supported by AI infrastructure demand and portfolio diversification, but risks include execution challenges and margin pressures. With 61.5% analyst buy ratings and technical momentum, the stock offers upside potential, though investors should weigh high P/E of 76.42 against earnings consistency and free cash flow trends.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
